Global X MSCI Argentina ETF vs Novo Nordisk A/S — how do they compare? Global X MSCI Argentina ETF trades at $91.07, while Novo Nordisk A/S trades at $46.39 (market cap $207.85B). The key difference: Novo Nordisk A/S pays a 3.81% dividend while Global X MSCI Argentina ETF pays none, and Global X MSCI Argentina ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| ARGT | NVO | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $102.94 | $63.98 |
52-Week Low | $67.55 | $35.29 |
Market Cap | — | $207.85B |
Enterprise Value | — | $222.55B |
Dividend Yield | — | 3.81% |
Signals from Pluang's Aura AI — not financial advice
ARGT, the Global X MSCI Argentina ETF, trades at $91.13, down 2.46% on the day, with a bearish technical signal from moving averages. Recent news highlights Argentina's economic reforms under the Milei administration as a potential catalyst. The ETF's valuation is noted as attractive relative to historical averages, though key financial ratios are not currently available in the provided data.
The outlook hinges on Argentina's continued economic stabilization. Upside potential exists if reforms sustain, but significant risks include political volatility and the ETF's heavy concentration in a few holdings like MercadoLibre, which could amplify losses if sentiment sours.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Trailing returns across standard periods
Latest headlines on both assets
ARGT seeks to provide investment results that correspond to the performance of the MSCI All Argentina 25/50 Index. It offers targeted exposure to some of the largest and most liquid companies operating in Argentina.
Read more on ARGT →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →